Bench
Library

Pentadeca Arginate

Repair & healing

Also known as PDA, BPC-157 arginate

BPC-157 supplied as an arginine salt. The same peptide, not a new molecule.

Read this first
Searching PubMed for 'pentadeca arginate' or 'BPC-157 arginate' returns zero results. The marketing claims of 90% oral bioavailability and 1000-fold greater acid stability have no published study behind them. Separately: 'Pentadeca' and 'Pentosan' are unrelated, Pentosan Polysulfate (Elmiron) is an FDA-approved sulfated polysaccharide for interstitial cystitis, not a peptide.

How it works

Identical peptide sequence to BPC-157. Every mechanistic claim made for it is transplanted from BPC-157 rodent work; no study has ever been performed on the arginate salt.

SubcutaneousOral

In the body

Half-life
25 minutes
Time to peak
24 min
90% gone after
1.4 h
Builds up to
1×
Steady state after about 2.1 h at once or twice daily.
12:09 PM

Shape of a single dose, modelled as one compartment with first-order absorption. The peak is normalised to 100% because bioavailability and volume of distribution are not published for most of these compounds.

Taken from BPC-157 animal data. No study of this salt form exists.

Doses

250 mcg, 750 mcgonce or twice dailyCommunity practice

Community protocols only. No registered human trial of PDA exists.

Vial sizes

5 mg10 mg20 mg

Commonly treated as good for 28 days refrigerated once reconstituted.

Side effects

  • No human safety data or toxicology exists for this salt form.

Cautions

  • The same considerations as BPC-157.

Status

Not approved. Note that the July 2026 FDA advisory vote covered BPC-157 free base and BPC-157 acetate. The arginate salt was not what was voted on.

Sources

Reference information for personal record-keeping. Not medical advice, and not a recommendation to use any of these compounds.